Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Abraxis BioScience and Specialised Therapeutics said that the New Zealand Medicines and Medical Devices Safety Authority (MEDSAFE) has granted marketing approval for Abraxane (nanoparticle albumin-bound paclitaxel) to treat metastatic breast cancer after failure of anthracycline therapy.
Subscribe to our email newsletter
Abraxane is a solvent-free chemotherapy treatment option for metastatic breast cancer which was developed using Abraxis BioScience’s proprietary nab technology platform.
Abraxis BioScience said that it has granted exclusive marketing rights to Specialised Therapeutics for Abraxane in New Zealand.
Accordingly, Specialised Therapeutics said that after receiving reimbursement approval from Pharmac, the New Zealand pharmaceutical reimbursement authority for Abraxane it will start the distribution of the product throughout New Zealand.
Patrick Soon-Shiong, executive chairman of Abraxis, said: “In the US and Australia Abraxane has rapidly become the taxane treatment of choice in its approved indication. We are pleased to provide this new treatment option for women in New Zealand with metastatic breast cancer.”
Carlo Montagner, CEO of Specialised Therapeutics, said: “Abraxane offers a safer and more efficacious taxane therapy for New Zealand women with metastatic breast cancer. Discussions with Pharmac will commence shortly and we hope to make Abraxane available as soon as an agreement with Pharmac is reached.”